Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
XERIS PHARMACEUTICALS INC (XERS) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/13/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "XERIS PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS"
08/10/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/11/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "XERIS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS Assets Current assets: Cash and cash equivalents $ 56,160 $ 45,716"
08/06/2019 8-K Quarterly results
05/09/2019 8-K Quarterly results
Docs: "XERIS PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS ITS PIPELINE Continuing to execute commercial build and launch readiness for Gvoke HypoPen™ and Gvoke PFS™ Dosed first patient in a Phase 2 study evaluating ready-to-use glucagon in EIH Advancing diazepam to Phase 2 based on recently reported favorable Phase 1 results Strengthened the balance sheet with February equity offering CHICAGO, IL; May 9, 2019 - Xeris Pharmaceuticals, Inc. , a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced financial results for the first quarter ended March 31, 2019, as well as pipeline and corporate highlights. "We have strong mo..."
03/06/2019 8-K Quarterly results
Docs: "XERIS PHARMACEUTICALS, INC. CONDENSED STATEMENT OF OPERATIONS Three Months Ended December 31, Twelve Months Ended December 31, 2018 2017 2018 2017 Grant income $ 754 $ 467 $ 2,365 $ 1,540"
11/07/2018 8-K Quarterly results
Docs: "XERIS PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS PIPELINE PROGRESS Glucagon pen NDA accepted for review by FDA Continuing to execute commercial build and launch readiness for glucagon pen Advancing pipeline of preclinical and clinical development-stage products CHICAGO, IL; November 7, 2018 - Xeris Pharmaceuticals, Inc. , a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced financial results for the third quarter ended September 30, 2018, as well as pipeline and corporate highlights. “A major achievement in the third quarter was the planned submission to the FDA of our NDA for the glucagon rescue pen for the treatment of severe hyp..."
08/13/2018 8-K Quarterly results
Docs: "XERIS PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS Successfully Completed Initial Public Offering Submitted New Drug Application for Glucagon Rescue Pen CHICAGO, IL; Aug 13, 2018 - Xeris Pharmaceuticals, Inc. , a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced financial results for the second quarter and corporate highlights. “We successfully completed our IPO in the second quarter and raised $89 million in net proceeds, which will fund multiple clinical programs, advance pre-clinical programs in other therapeutic areas, as well as build out our commercial organization in preparation for the commercial launch of our lead..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy